Michael Schnekenburger

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7444523/publications.pdf

Version: 2024-02-01

78 papers	4,252 citations	109321 35 h-index	110387 64 g-index
79 all docs	79 docs citations	79 times ranked	6464 citing authors

#	Article	IF	Citations
1	Chemopreventive and therapeutic effects of curcumin. Cancer Letters, 2005, 223, 181-190.	7.2	771
2	Long term low-dose arsenic exposure induces loss of DNA methylation. Biochemical and Biophysical Research Communications, 2007, 352, 188-192.	2.1	272
3	Histone deacetylase 6 in health and disease. Epigenomics, 2015, 7, 103-118.	2.1	174
4	Chromium Cross-Links Histone Deacetylase 1-DNA Methyltransferase 1 Complexes to Chromatin, Inhibiting Histone-Remodeling Marks Critical for Transcriptional Activation. Molecular and Cellular Biology, 2007, 27, 7089-7101.	2.3	138
5	Induction of apoptosis by curcumin: mediation by glutathione S-transferase P1-1 inhibition. Biochemical Pharmacology, 2003, 66, 1475-1483.	4.4	124
6	Sustained exposure to the DNA demethylating agent, 2â€²-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy. Biochemical Pharmacology, 2011, 81, 364-378.	4.4	115
7	HDAC1 bound to the Cyp1a1 promoter blocks histone acetylation associated with Ah receptor-mediated trans-activation. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2007, 1769, 569-578.	2.4	111
8	Selective Non-nucleoside Inhibitors of Human DNA Methyltransferases Active in Cancer Including in Cancer Stem Cells. Journal of Medicinal Chemistry, 2014, 57, 701-713.	6.4	111
9	Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics, 2011, 3, 581-609.	2.1	97
10	Protein Kinase and HDAC Inhibitors from the Endophytic Fungus Epicoccum nigrum. Journal of Natural Products, 2014, 77, 49-56.	3.0	97
11	Genomewide Analysis of Aryl Hydrocarbon Receptor Binding Targets Reveals an Extensive Array of Gene Clusters that Control Morphogenetic and Developmental Programs. Environmental Health Perspectives, 2009, 117, 1139-1146.	6.0	90
12	Plant-derived epigenetic modulators for cancer treatment and prevention. Biotechnology Advances, 2014, 32, 1123-1132.	11.7	90
13	Epigenetics Offer New Horizons for Colorectal Cancer Prevention. Current Colorectal Cancer Reports, 2012, 8, 66-81.	0.5	87
14	UNBS1450, a steroid cardiac glycoside inducing apoptotic cell death in human leukemia cells. Biochemical Pharmacology, 2011, 81, 13-23.	4.4	86
15	Effect of chemopreventive agents on glutathione S-transferase P1-1 gene expression mechanisms via activating protein 1 and nuclear factor kappaB inhibition. Biochemical Pharmacology, 2004, 68, 1101-1111.	4.4	75
16	Natural chalcones as dual inhibitors of HDACs and NF-Î¹B. Oncology Reports, 2012, 28, 797-805.	2.6	71
17	Chromatin-modifying agents in anti-cancer therapy. Biochimie, 2012, 94, 2264-2279.	2.6	67
18	Regulation of epigenetic traits of the glutathione S-transferase P1 gene: from detoxification toward cancer prevention and diagnosis. Frontiers in Pharmacology, 2014, 5, 170.	3.5	66

#	Article	IF	Citations
19	An Introduction to the Molecular Mechanisms of Apoptosis. Annals of the New York Academy of Sciences, 2003, 1010, 1-8.	3.8	65
20	Histone deacetylase modulators provided by Mother Nature. Genes and Nutrition, 2012, 7, 357-367.	2.5	60
21	Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer. Molecules, 2016, 21, 1608.	3.8	58
22	MicroRNAs in cancer management and their modulation by dietary agents. Biochemical Pharmacology, 2012, 83, 1591-1601.	4.4	57
23	GATAâ€1: Friends, Brothers, and Coworkers. Annals of the New York Academy of Sciences, 2004, 1030, 537-554.	3.8	56
24	Discovery and characterization of Isofistularin-3, a marine brominated alkaloid, as a new DNA demethylating agent inducing cell cycle arrest and sensitization to TRAIL in cancer cells. Oncotarget, 2016, 7, 24027-24049.	1.8	54
25	DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs. Biochemical Pharmacology, 2012, 83, 858-865.	4.4	49
26	Role of Histone Acetylation in Cell Cycle Regulation. Current Topics in Medicinal Chemistry, 2015, 16, 732-744.	2.1	49
27	4-Hydroxybenzoic acid derivatives as HDAC6-specific inhibitors modulating microtubular structure and HSP90Î± chaperone activity against prostate cancer. Biochemical Pharmacology, 2016, 99, 31-52.	4.4	48
28	Regulation of glutathione S-transferase P1-1 gene expression by NF-kappaB in tumor necrosis factor alpha-treated K562 leukemia cells. Biochemical Pharmacology, 2004, 67, 1227-1238.	4.4	44
29	Curcumin-Induced Cell Death in Two Leukemia Cell Lines: K562 and Jurkat. Annals of the New York Academy of Sciences, 2003, 1010, 389-392.	3.8	43
30	Antiproliferative and proapoptotic activities of 4-hydroxybenzoic acid-based inhibitors of histone deacetylases. Cancer Letters, 2014, 343, 134-146.	7.2	40
31	Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways. Pharmacological Research, 2018, 129, 337-356.	7.1	40
32	Aryl Hydrocarbon Receptor Ligands of Widely Different Toxic Equivalency Factors Induce Similar Histone Marks in Target Gene Chromatin. Toxicological Sciences, 2011, 121, 123-131.	3.1	39
33	5-aza-2â€²-deoxycytidine-mediated c-myc Down-regulation Triggers Telomere-dependent Senescence by Regulating Human Telomerase Reverse Transcriptase in Chronic Myeloid Leukemia. Neoplasia, 2014, 16, 511-528.	5.3	39
34	Tumor necrosis factor Î± induces Î³-glutamyltransferase expression via nuclear factor-ÎºB in cooperation with Sp1. Biochemical Pharmacology, 2009, 77, 397-411.	4.4	37
35	Sp proteins play a critical role in histone deacetylase inhibitorâ€mediated derepression of CYP46A1 gene transcription. Journal of Neurochemistry, 2010, 113, 418-431.	3.9	37
36	Expression of glutathione S-transferase P1-1 in leukemic cells is regulated by inducible AP-1 binding. Cancer Letters, 2004, 216, 207-219.	7.2	36

#	Article	IF	Citations
37	Epigenetic modulators from â€œThe Big Blueâ€• A treasure to fight against cancer. Cancer Letters, 2014, 351, 182-197.	7.2	36
38	Natural compounds as inflammation inhibitors. Genes and Nutrition, 2011, 6, 89-92.	2.5	35
39	Properly Substituted Analogues of BIX-01294 Lose Inhibition of G9a Histone Methyltransferase and Gain Selective Anti-DNA Methyltransferase 3A Activity. PLoS ONE, 2014, 9, e96941.	2.5	35
40	Novel inhibitors of human histone deacetylases: Design, synthesis and bioactivity of 3-alkenoylcoumarines. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3797-3801.	2.2	35
41	Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatments. Current Topics in Medicinal Chemistry, 2015, 16, 745-776.	2.1	35
42	Valproic acid perturbs hematopoietic homeostasis by inhibition of erythroid differentiation and activation of the myelo-monocytic pathway. Biochemical Pharmacology, 2011, 81, 498-509.	4.4	34
43	Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells. Clinical Epigenetics, 2019, 11, 68.	4.1	30
44	Naturally Occurring Regulators of Histone Acetylation/Deacetylation. Current Nutrition and Food Science, 2010, 6, 78-99.	0.6	29
45	Reversible epigenetic fingerprint-mediated glutathione-S-transferase P1 gene silencing in human leukemia cell lines. Biochemical Pharmacology, 2011, 81, 1329-1342.	4.4	29
46	Repression of Ah receptor and induction of transforming growth factor-Î² genes in DEN-induced mouse liver tumors. Toxicology, 2008, 246, 242-247.	4.2	27
47	Curcumin Stability and Its Effect on GlutathioneS-Transferase P1-1 mRNA Expression in K562 Cells. Annals of the New York Academy of Sciences, 2004, 1030, 442-448.	3.8	25
48	Bis(4-hydroxy-2H-chromen-2-one): Synthesis and effects on leukemic cell lines proliferation and NF-ÎºB regulation. Bioorganic and Medicinal Chemistry, 2014, 22, 3008-3015.	3.0	23
49	Discovery and Characterization of R/S-N-3-Cyanophenyl-Nâ€²-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzo[b]pyran-4-yl)-N-methylguanidine, a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity against Cancer Cell Lines. Journal of Medicinal Chemistry, 2017, 60, 4714-4733.	6.4	22
50	Anticancer potential of naturally occurring immunoepigenetic modulators: A promising avenue?. Cancer, 2019, 125, 1612-1628.	4.1	22
51	The Ah Receptor Recruits IKKÎ± to Its Target Binding Motifs to Phosphorylate Serine-10 in Histone H3 Required for Transcriptional Activation. Toxicological Sciences, 2014, 139, 121-132.	3.1	21
52	Tetrahydrobenzimidazole TMQ0153 triggers apoptosis, autophagy and necroptosis crosstalk in chronic myeloid leukemia. Cell Death and Disease, 2020, 11, 109.	6.3	21
53	Increased glutathione S-transferase P1-1 expression by mRNA stabilization in hemin-induced differentiation of K562 cells. Biochemical Pharmacology, 2004, 68, 1269-1277.	4.4	20
54	COX-2 inhibitors block chemotherapeutic agent-induced apoptosis prior to commitment in hematopoietic cancer cells. Biochemical Pharmacology, 2011, 82, 1277-1290.	4.4	20

#	Article	IF	Citations
55	Nutritional Epigenetic Regulators in the Field of Cancer. , 2015, , 393-425.		20
56	The dialkyl resorcinol stemphol disrupts calcium homeostasis to trigger programmed immunogenic necrosis in cancer. Cancer Letters, 2018, 416, 109-123.	7.2	20
57	Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells. Clinical Epigenetics, 2020, 12, 69.	4.1	19
58	Tumor necrosis factor alpha inhibits aclacinomycin A-induced erythroid differentiation of K562 cells via GATA-1. Cancer Letters, 2006, 240, 203-212.	7.2	17
59	Valproic acid regulates erythro-megakaryocytic differentiation through the modulation of transcription factors and microRNA regulatory micro-networks. Biochemical Pharmacology, 2014, 92, 299-311.	4.4	17
60	Expression of glutathione S-transferase P1-1 in differentiating K562: role of GATA-1. Biochemical and Biophysical Research Communications, 2003, 311, 815-821.	2.1	16
61	Transcriptional and post-transcriptional regulation of glutathione S-transferase P1 expression during butyric acid-induced differentiation of K562 cells. Leukemia Research, 2006, 30, 561-568.	0.8	16
62	Synergistic AML Cell Death Induction by Marine Cytotoxin (+)-1(R), 6(S), 1â€™(R), 6â€™(S), 11(R), 17(S)-Fistularin-3 and Bcl-2 Inhibitor Venetoclax. Marine Drugs, 2018, 16, 518.	4.6	16
63	Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia. Biochemical Pharmacology, 2020, 173, 113698.	4.4	15
64	The DNA hypomethylating agent, 5â€azaâ€2â€²â€deoxycytidine, enhances tumor cell invasion through a transcriptionâ€dependent modulation of MMPâ€1 expression in human fibrosarcoma cells. Molecular Carcinogenesis, 2015, 54, 24-34.	2.7	14
65	Epigenetically induced changes in nuclear textural patterns and gelatinase expression in human fibrosarcoma cells. Cell Proliferation, 2013, 46, 127-136.	5.3	12
66	Dual Induction of Mitochondrial Apoptosis and Senescence in Chronic Myelogenous Leukemia by Myrtucommulone A. Anti-Cancer Agents in Medicinal Chemistry, 2015, 15, 363-373.	1.7	12
67	HDAC6â€”An Emerging Target Against Chronic Myeloid Leukemia?. Cancers, 2020, 12, 318.	3.7	11
68	Targeting inflammatory cell signaling mechanisms: a promising road to new therapeutic agents in chemoprevention and cancer therapy. Journal of Experimental Therapeutics and Oncology, 2011, 9, 1-4.	0.5	11
69	The Fungal Metabolite Eurochevalierine, a Sequiterpene Alkaloid, Displays Anti-Cancer Properties through Selective Sirtuin 1/2 Inhibition. Molecules, 2018, 23, 333.	3.8	10
70	Discovery of Sulforaphane as an Inducer of Ferroptosis in U-937 Leukemia Cells: Expanding Its Anticancer Potential. Cancers, 2022, 14, 76.	3.7	9
71	Human telomerase reverse transcriptase depletion potentiates the growth-inhibitory activity of imatinib in chronic myeloid leukemia stem cells. Cancer Letters, 2020, 469, 468-480.	7.2	8
72	The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia. Pharmacological Research, 2020, 160, 105058.	7.1	7

#	Article	IF	Citations
73	Editorial (Thematic Issue: Novel Pharmaceutical Approaches by Natural Compound-Derived Epigenetic) Tj ETQq1 1 0.784314 rgBT /Over Medicinal Chemistry, 2015, 16, 677-679.	2.1	3
74	Conference Scene: Omic technologies in human disease: extending the network of epigenetic control. Epigenomics, 2011, 3, 539-541.	2.1	2
75	Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitors. Biochemical Pharmacology, 2021, 188, 114526.	4.4	2
76	Synthesis, Enzyme Assays and Molecular Docking Studies of Fluorina ted Bioisosteres of Santacruzamate A as Potential HDAC Tracers. Letters in Drug Design and Discovery, 2017, 14, .	0.7	2
77	Perspectives in Medicinal Chemistry: DNA Methylation and Demethylation Mechanisms as Therapeutic Targets?. Current Topics in Medicinal Chemistry, 2015, 16, 807-808.	2.1	0
78	Natural Compounds as Epigenetic Modulators in Cancer. Proceedings (mdpi), 2019, 11, .	0.2	0